An article by Kai Kupferschmidt in Science magazine gives a comprehensive survey of current psychedelic research. “High Hopes” focuses on the work of Heffter board member Stephen Ross and includes quotes from board members Roland Griffiths and Franz Vollenweider.
“Albert Hofmann, the Swiss chemist who discovered LSD and psilocybin, believed that these psychedelic drugs might be useful in treating mental illness; the company he worked for, Sandoz, sent them to doctors around the world for experimentation in the 1950s and ’60s. But then, the drugs fell from grace, and most of the research was stopped. Now, researchers have rediscovered psychedelic drugs for their unmatched ability to alter the way the brain processes information, and they are studying them as possible treatments for depression, addiction, anxiety, cluster headaches, and other disorders. But this remains a contentious field, and the scientists studying these drugs face many difficult questions.”